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Chromosomal translocation requires formation of
paired double-strand DNA breaks (DSBs) on heterol-
ogous chromosomes. One of the most well charac-
terized oncogenic translocations juxtaposes c-myc
and the immunoglobulin heavy-chain locus (IgH) and
is found in Burkitt’s lymphomas in humans and plas-
macytomas in mice. DNA breaks in IgH leading to
c-myc/IgH translocations are created by activation-
induced cytidine deaminase (AID) during antibody
class switch recombination or somatic hypermuta-
tion. However, the source of DNA breaks at c-myc is
not known. Here, we provide evidence for the c-myc
promoter region being required in targeting AID-
mediated DNA damage to produce DSBs in c-myc
that lead to c-myc/IgH translocations in primary B
lymphocytes. Thus, in addition to producing somatic
mutations and DNA breaks in antibody genes, AID is
also responsible for the DNA lesions in oncogenes
that are required for their translocation.
INTRODUCTION
Chromosome translocations have been proposed to require
formation of pairs of double-strand DNA breaks (DSBs) and
trans-chromosomal ligation of the broken ends (Richardson
and Jasin, 2000). Among somatic cells, mature B lymphocytes
are particularly prone to DSB formation in Ig loci during antibody
gene diversification reactions and to malignant transformation by
Ig translocation (Adams et al., 1982, 1983, 1985; Cory et al., 1983;
Crews et al., 1982; Dalla-Favera et al., 1983; Erikson et al., 1983;
Hamlyn and Rabbitts, 1983; Jankovic et al., 2007; Kuppers and1028 Cell 135, 1028–1038, December 12, 2008 ª2008 Elsevier Inc.Dalla-Favera, 2001; Leder et al., 1983; Marcu et al., 1983; Stanton
et al., 1983; Taub et al., 1982).
Two different reactions diversify antibody genes in mature
B cells: class switch recombination (CSR) and somatic hypermu-
tation (SHM). CSR involves deletion of DNA sequences and
replacement of one antibody constant region for another while re-
taining the specificity of the antigen receptor (Chaudhuri et al.,
2007; Stavnezer et al., 2008). In contrast, SHM introduces non-
templated nucleotide changes in antibody variable region genes,
producing variants with differing affinity for antigen (Di Noia and
Neuberger, 2007; Peled et al., 2008). Although these reactions
are very different, they are both initiated by activation-induced
cytidine deaminase (AID), an enzyme that is expressed primarily
in germinal center B cells (Muramatsu et al., 1999, 2000; Revy
et al., 2000). The same enzyme is also essential for c-myc/IgH
translocations in primary B cells and mouse plasmacytomas
(Kovalchuk et al., 2007; Potter, 2003; Ramiro et al., 2004, 2006;
Takizawa et al., 2008).
AID initiates CSR and SHM by deaminating cytosine residues
in single-stranded DNA, which is exposed during transcription
(Bransteitter et al., 2003; Chaudhuri et al., 2003; Di Noia and Neu-
berger, 2002; Dickerson et al., 2003; Imai et al., 2003; Petersen-
Mahrt et al., 2002; Pham et al., 2003; Ramiro et al., 2003). The
resulting U:G mismatch is recognized by either uracyl DNA glyco-
sylase or mismatch repair proteins and processed by one of
several DNA repair pathways to produce point mutations in vari-
able regions or a combination of mutations and DSBs in switch
regions (Di Noia and Neuberger, 2007; Peled et al., 2008; Rada
et al., 2002; Stavnezer et al., 2008). AID introduces multiple
DSBs in switch regions during CSR, as evidenced by internal de-
letions (Dudley et al., 2002; Nagaoka et al., 2002; Petersen et al.,
2001; Reina-San-Martin et al., 2003) and accumulation of foci of
DNA repair factors at the IgH locus preceding CSR (Petersen
et al., 2001; Reina-San-Martin et al., 2004). Deletions and dupli-
cations are less frequent in Ig variable regions, accounting for
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Figure 1. The MycD Allele Is Protected from Translocating to the IgH
(A) Schematic representation of wild-type (Myc+) and mutant (MycD) c-myc alleles. The dashed bracket indicates the region deleted and replaced by a loxP site
(triangle) in the MycD allele.
(B) Genotyping summary from the indicated MycD/+ crosses.
(C) RNA-FISH showing biallelic versus monoallelic c-myc transcription in wild-type (WT) versus MycD/+ cells, respectively.
(D) Diagram showing the location of the primers used in the PCR assay to detect derivative chromosome 12 (der12, black arrows) and derivative chromosome 15
(der15, green arrows) c-myc/IgH translocations. The table summarizes the number of allele-specific der12 and der15 c-myc/IgH translocations in activated MycD/+
B cells, as determined by sequencing. Data are from three independent experiments.5% of all hypermutations (Goossens et al., 1998; Wilson et al.,
1998). c-myc translocates to both Ig variable and switch regions,
and in both cases the translocations are AID dependent (Dorsett
et al., 2007; Ramiro et al., 2004).
In addition to targeting Ig loci, AID also produces mutations in
a number of other genes, including oncogenes (Gordon et al.,
2003; Liu et al., 2008; Muschen et al., 2000; Pasqualucci et al.,
1998, 2001; Shen et al., 1998). However, mutations in c-myc
either are absent (Pasqualucci et al., 2001; Shen et al., 1998) or
occur at a rate that is several orders of magnitude lower than in
IgH (Liu et al., 2008). In addition, the available sequence analysis
shows no evidence of AID-dependent deletions or duplications in
c-myc or other oncogenes that might suggest AID-dependent
DSB formation (Gordon et al., 2003; Liu et al., 2008; Muschen
et al., 2000; Pasqualucci et al., 1998, 2001; Shen et al., 1998). Fur-
thermore, AID-induced lesions in genes other than antibody
genes appear to be repaired by a pathway that is distinct from
and less error prone than lesions in IgH (Liu et al., 2008). Indeed,
when DSBs have been detected in c-myc in human B cells, they
have been found to be AID independent (Zan et al., 2003).
One potential source for the DSBs in c-myc is fragile DNA
segments that are prone to form non-B-DNA configurations,
including Z-DNA, triple-helical H-DNA, and G-quadruplex DNA
(reviewed in Liu and Levens, 2006; Marcu et al., 1992; Spencer
and Groudine, 1991; Wierstra and Alves, 2008). These sequences
are particularly susceptible to AID-independent DNA damage
and DSB formation during transcription or replication, but also
to environmental agents and metabolic stress, and they have
been implicated as a source of the DSBs in c-myc that lead to
translocation (reviewed in Reddy and Vasquez, 2005).Here, we report on experiments that examine the role of the
c-myc promoter and AID in producing the lesions in c-myc that
lead to c-myc/IgH translocations in mature B cells in vivo.
RESULTS
c-myc is transcribed from several promoters distributed in a
region surrounding the noncoding first exon of the gene (Wier-
stra and Alves, 2008). To determine whether c-myc transcrip-
tion is required for translocation to IgH, we used homologous
recombination in embryonic stem cells to delete a 2.2 kb geno-
mic fragment that includes the region corresponding to c-myc
promoters P0, P1, and P2 (Figure 1A, and Figure S1 available
online). MycD/+ mice were born at nearly Mendelian ratio
(Figure 1B), and B cell development and activation in response
to mitogenic stimuli were unaltered in heterozygous mice
(Figure S1).
To examine the transcriptional status of the MycD allele, we
performed RNA fluorescence in situ hybridization (Osborne
et al., 2007). Among the Myc+/+ B cells with transcriptionally
active alleles (n = 168), 76% had one active c-myc allele, and
24% had two active alleles. In striking contrast, 97% of the tran-
scriptionally active MycD/+ B cells (n = 86) had one silent allele,
demonstrating that only one of the two alleles was efficiently tran-
scribed in mutant mice (Figure 1C). Consistent with the reported
lethality of c-myc deletion (Davis et al., 1993), the MycD mutation
resulted in intercrosses between MycD/+ mice that failed to pro-
duce any MycD/D homozygous mutants (Figure 1B). We conclude
that c-myc transcription is severely impaired by the MycD
mutation.Cell 135, 1028–1038, December 12, 2008 ª2008 Elsevier Inc. 1029
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Figure 2. Cre-Mediated c-myc/IgH Trans-
locations
(A) Schematic representation of the MycD, MycI,
and IgHI alleles with the PCR primers for detecting
der12 c-myc/IgH translocations. Triangles repre-
sent loxP sites, and circles point to recognition
sequences for I-SceI.
(B) Translocations by retroviral Cre. Ethidium
bromide stained agarose gel with 0.5 kb PCR
products corresponding to precise loxP-to-loxP
c-myc/IgH translocations (as verified by sequenc-
ing). B lymphocytes of the indicated genotypes
were stimulated with LPS and IL-4 and infected
with retroviruses that direct expression of Cre.
The number of cells that were assayed in each
reaction is indicated. Data are from two indepen-
dent experiments.
(C) Translocations in AIDCre B cells. Agarose gel
with 0.5 kb PCR products corresponding to pre-
cise loxP-to-loxP c-myc/IgH translocations (as
verified by sequencing). AIDCre B cells of the indi-
cated genotypes were stimulated with LPS and
IL-4. The number of cells assayed in each reaction
is indicated. Data are from two independent
experiments.To examine the effects of the MycD mutation on c-myc/IgH
translocations, we assayed for these events in heterozygous
MycD/+ B cells stimulated with lipopolysaccharide (LPS) and
IL-4, using a previously described PCR assay to detect both de-
rivative 12 and 15 chromosomes (Figure 1D and Figure S2).
Translocations were detected in MycD/+ mice, but sequence
analysis revealed that 22 of 23 of these were IgH fusions to the
wild-type Myc+ allele (Figure 1D). Thus, the MycD mutation
drastically reduces c-myc’s propensity to undergo oncogenic
chromosomal translocations to IgH.
c-myc/IgH Translocations Induced by Cre
The IgH locus on mouse chromosome 12 and the c-myc locus on
chromosome 15 colocalize in transcription factories in activated
B lymphocytes, and this physical proximity has been proposed
to facilitate c-myc/IgH translocations (Osborne et al., 2007;
Parada et al., 2004; Roix et al., 2003).
To determine whether the MycD allele was accessible for trans-
location, we made use of the phage-derived Cre-loxP recombi-
nase system (Van Duyne, 2001). Cre recognizes 34 nucleotide
loxP sites and catalyzes DNA recombination between two such
sites. Recombination requires that Cre gain access to the DNA
target, and the efficiency of the reaction is inversely proportional
to the distance between loxP sites (Burgess and Kleckner, 1999;
Egli et al., 2004; Yu and Bradley, 2001). To test for Cre-mediated
translocations between the loxP site on the MycD allele and IgH,
we introduced a single loxP site into IgH, upstream of the switch m
region (IgHI/+ mice, Figure 2A and Figure S3). As a control for the
MycD allele, we also introduced a single loxP site into the first in-
tron of intact c-myc (MycI/+ mice, Figure 2A and Figure S4). IgHI/+
and MycI/+ mice showed normal B lymphocyte development and
switching in response to LPS and IL-4 stimulation (Figures S3
and S4 and data not shown). Compound heterozygous B cells
bearing either MycD or MycI and IgHI (MycD/IgHI and MycI/IgHI,
respectively) were tested for Cre-mediated translocations with1030 Cell 135, 1028–1038, December 12, 2008 ª2008 Elsevier Inc.a retrovirus expressing Cre. By semiquantitative analysis, we
found that the frequencies of c-myc/IgH translocations in
MycD/IgHI and MycI/IgHI B cells expressing Cre were indistin-
guishable (0.5 3 105 for der12) (Figure 2B).
To examine the nature of Cre-mediated interchromosomal
junctions, we sequenced eight candidate translocations. Irre-
spective of whether the translocations originated from MycD/
IgHI or MycI/IgHI B cells, the breakpoints were always precisely
at the loxP site. To corroborate these results in the absence of
retroviral Cre overexpression, we crossed the MycD/IgHI and
MycI/IgHI mice to mice in which Cre expression is under the con-
trol of regulatory elements of aicda (AIDCre/+, Figure S5). Cre-
mediated translocations were readily detected in both MycD/
IgHI/AIDCre and MycI/IgHI/AIDCre B lymphocytes upon mitogenic
stimulation in vitro, and even in Peyer’s Patches in vivo (Figures
2C and Figure S6). Thus, Cre rescues translocation of the mutant
MycD allele in activated B cells in vitro and in vivo. We conclude
that both the active (MycI) and silent (MycD) alleles reside in
Cre-accessible nuclear compartments and remain in sufficient
spatial proximity to IgH to permit translocation irrespective of
c-myc’s transcriptional status.
DSBs in c-myc Catalyzed by I-SceI
AID-induced DSBs along the IgH locus can be detected by com-
bining immunocytochemistry to detect accumulation of 53BP1
foci and fluorescence in situ hybridization to localize IgH (Figure 3)
(Reina-San-Martin et al., 2004). Background levels of colocaliza-
tion of 53BP1 foci and IgHwere found in AID-deficient B cells, and
the frequency increased to 42.5% in AID-sufficient B cells (Fig-
ure 3A) (Reina-San-Martin et al., 2004). In contrast, when we
examined c-myc by the same technique, we found no AID-
dependent increase in 53BP1 foci during CSR (Figure 3A). Retro-
viral overexpression of AID did, however, result in DNA damage
at c-myc, as determined by increased colocalization of 53BP1
foci (12.2% versus 4.3% with control, p = 0.007; Figure 3B) and
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Figure 3. I-SceI-Induced Breaks
(A) Immuno-FISH analysis of 53BP1 DNA damage foci at IgH or c-myc loci in activated B cells. Representative images and table show colocalization frequencies
as percentage of cells analyzed in LPS and IL-4 stimulated wild-type (WT) or AID/ B lymphocytes. The number of cells analyzed is shown in parentheses. Data
are from three independent experiments.
(B) Immuno-FISH analysis of AID-induced 53BP1 DNA damage foci in AID/ B cells infected with AID or empty virus control. Representative images and table
showing colocalization frequencies at c-myc (p = 0.007 with Student’s t test).
(C) Immuno-FISH analysis of I-SceI induced 53BP1 DNA damage foci in IgHI/+AID/ (top) or MycI/+AID/ B cells (bottom). Representative images and table
show colocalization frequencies at IgH or c-myc (as indicated) in I-SceI- or I-SceI*-expressing B lymphocytes.accumulation of mutations in intron 1 (1.23 104 versus less than
0.073 104 with control, p = 0.0005; Table S1). Thus, our immu-
nofluorescence in situ hybridization (immuno-FISH) experiments
are in agreement with the sequencing data and fail to show evi-
dence for AID-induced DNA damage on c-myc during CSR under
physiologic circumstances (Liu et al., 2008; Pasqualucci et al.,
2001; Shen et al., 1998). However, c-myc can be an AID target
when AID is overexpressed.
To examine the consequence of DSB formation at c-myc, we
used the yeast-derived I-SceI endonuclease, which recognizes
an 18 bps site that is otherwise absent from the mouse genome
(reviewed in Stoddard, 2005). DNA breaks were created in the
presence or absence of AID with I-SceI used to cut at cognate
target sites introduced into the MycI and IgHI alleles (Figure 2A
and Figures S3 and S4). Similar to AID-induced DNA damage,
retroviral expression of I-SceI in activated MycI/+AID/ or
IgHI/+AID/ B lymphocytes produced frequent DSBs in c-myc
or IgH, respectively. As determined by immuno-FISH, 30.8%
of MycI/+ B cells expressing I-SceI showed colocalization ofc-myc and 53BP1, and 21.9% of IgHI/+ B cells exhibited
IgH/53BP1 colocalization (Figure 3C). Control B lymphocytes
infected with a catalytically inactive form of I-SceI (I-SceI*)
showed background levels of DNA damage at c-myc or IgH
(Figure 3C). We conclude that I-SceI efficiently targets MycI
and IgHI in activated B cells.
c-myc/IgH Translocations Catalyzed by I-SceI
To determine whether DSBs produced by I-SceI can serve as
substrates for c-myc/IgH translocation, we assayed for these
events in LPS and IL-4-stimulated MycI/+IgHI/+AID/ B cells
expressing I-SceI or I-SceI* (Figure 4). Whereas we found no
translocation with the retrovirus alone or I-SceI*, I-SceI expres-
sion produced der15 translocations at a rate of 10 3 105 (Fig-
ure 4B, Figures S7 and S10, and data not shown; note that
although we assayed both der12 and der15 translocations, the
close proximity of the binding sites of the der12 primers to the
I-SceI sequences and processing of the DNA ends [see below]
appears to result in the underestimation of their frequency).Cell 135, 1028–1038, December 12, 2008 ª2008 Elsevier Inc. 1031
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Figure 4. I-SceI-Induced Translocations in
AID-Deficient B Lymphocytes
(A) Schematic representation of the MycI, Myc+,
and IgHI alleles with the PCR primers for detecting
der12 and der15 c-myc/IgH translocations.
Circles point to the position of the I-SceI sites.
(B) I-SceI rescues translocations in the absence of
AID. Representative agarose gels are shown, with
PCR products corresponding to c-myc/IgH trans-
locations (as verified by sequencing and/or South-
ern blot, see Figure S7). MycI/+IgHI/+AID/ B cells
were stimulated with LPS and IL-4 and infected
with I-SceI or I-SceI* control retroviruses. In each
lane, 100,000 cells were assayed. Data are from
three independent experiments.
(C) Map of translocation breakpoints from I-SceI-
expressing MycI/+IgHI/+AID/ B cells (see also
Table S2). Arrows point to c-myc/IgH translo-
cation breakpoints for der12 (black) or der15
(green).Thus, DSBs introduced by I-SceI in c-myc and IgH result in
c-myc/IgH transchromosomal rearrangements.
Translocation breakpoints were found precisely at the I-SceI
site and also at distances of up to 2178 bps from the site of
the DSB (Figure 4C, and Table S2). The average distance of the
breakpoint position from the I-SceI site on c-myc was 50 bps for
der12 and 1744 bps for der15, and for IgH it was 39 bps for der12
and 91 bps for der15 (Table S2). Out of 21 translocation junc-
tions, 19 involved 1–7 bps of microhomology (average microho-
mology of 2.9 bps) and two included insertions (Figure 5 and
Table S2). We conclude that repair of I-SceI breaks frequently
involves processing of the ends and microhomology-mediated
joining.
Source of DSB in c-myc during c-myc/IgH Translocation
To determine whether I-SceI breaks can be joined to AID-induced
lesions, we examined MycI/+ B cells infected with I-SceI- or
I-SceI*-encoding retroviruses. Baseline levels of AID-mediated
translocation were enhanced by I-SceI cutting in MycI/+ B cells
(for der15 I-SceI*, 0.2 3 105, versus I-SceI, 0.8 3 105, p =
0.0002; Figure 5B and Figure S8). Consistent with this enhance-
ment, 15 of 17 translocations produced in MycI/+ B cells infected
with I-SceI were MycI to IgH translocations, while only two
involved the wild-type Myc+ allele (Table S3). Whereas the break-
points for c-myc/IgH translocations cloned from wild-type
control B cells were spread over 1.4 kb surrounding the first
exon of c-myc, ten of 15 I-SceI induced MycI breakpoints were
found precisely at the I-SceI site, and the remainder mapped
within 74 bps of the site (Figure 5C and Table S3). In contrast to
the breakpoints produced by the joining of two I-SceI breaks in
the absence of AID (Figure 4C, Table S2), seven of the junctions
between an I-SceI DSB in c-myc and an AID lesion in IgH
were blunt, two had an insertion, and the remaining six showed
1–3 bps of microhomology (overall average microhomology,
0.8 bps; Figure 5D, Table S3). A similar relationship between1032 Cell 135, 1028–1038, December 12, 2008 ª2008 Elsevier Inc.direct versus microhomology-mediated joins is found in c-myc/
IgH translocations in wild-type B cells (Figure 5D and Table S4)
and in physiological CSR, where 30%–60% of the joints are blunt
and the remainder use 1–4 bps of microhomology (reviewed in
Chaudhuri et al., 2007; Stavnezer et al., 2008).
Whereas I-SceI-induced DSBs in c-myc enhanced transloca-
tion frequency (Figure 5B), we found no difference in transloca-
tion frequency between IgHI/+ B cells infected with I-SceI or
I-SceI* (for der15, 0.14 3 105 versus 0.2 3 105, respectively;
Figure S9). The breakpoint was at the I-SceI cognate site in
two out of four translocations involving the IgHI allele, confirming
that similar to MycI, IgHI was also substrate for I-SceI cleavage
and recombination (Figure S9). Therefore, although I-SceI gener-
ates DSBs at c-myc and IgH with comparable efficiency (Fig-
ure 3C), it enhances the frequency of c-myc/IgH translocation
in MycI/+ but not IgHI/+ B cells. We conclude that I-SceI-induced
breaks in c-myc or IgH can be joined to AID-produced breaks in
IgH or c-myc, respectively, to create c-myc/IgH translocations.
In addition, we find that DSBs in c-myc but not IgH are limiting
for translocation since a single I-SceI break in c-myc but not
IgH enhances translocation.
To determine whether the source of the DSB alters the fre-
quency of translocation, we compared the incidence of c-myc/
IgH transchromosomal rearrangements in MycI/+IgHI/+AID/
B cells infected with AID- or I-SceI- or Cre-expressing retrovi-
ruses. We found that the rate of translocation was similar for all
three DNA damage-inducing enzymes (for der15, 5 3 105 for
AID, 103 105 for I-SceI, and 33 105 for Cre, Figure 6 and Fig-
ure S10). We conclude that the rate of c-myc/IgH translocation is
similar irrespective of whether the DSBs are induced by AID,
I-SceI, or Cre.
To determine whether AID is essential to create the breaks in
c-myc that lead to c-myc/IgH translocation, we induced DSBs in
the IgH locus of IgHI/+AID/ or the c-myc locus of MycI/+AID/
B cells using I-SceI. In contrast to IgHI/+MycI/+AID/ B cells
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Figure 5. I-SceI-Induced Translocations in
AID-Sufficient B Lymphocytes
(A) Schematic representation of the MycI, Myc+,
and IgH+ alleles with the PCR primers for detect-
ing der12 and der15 c-myc/IgH translocations.
The circle points to the recognition sequence for
I-SceI.
(B) I-SceI-directed translocations in the presence
of AID. Representative agarose gels are shown,
with PCR products corresponding to c-myc/IgH
translocations (as verified by sequencing and/or
Southern blot, see Figure S8). MycI/+ B cells
were stimulated with LPS and IL-4 and infected
with I-SceI (three independent experiments) or
I-SceI* control. In each lane, 100,000 cells were
assayed.
(C) Map of translocation breakpoints from stimu-
lated MycI/+ B cells infected with I-SceI (see also
Table S3). Filled arrows point to c-myc/IgH trans-
location breakpoints from der12 (black) or der15
(green). Empty arrows indicate the distribution of
breakpoints obtained in the absence of I-SceI.
(D) Table shows summary of the extent of junc-
tional microhomology from c-myc/IgH transloca-
tions (see Tables S2, S3, and S4).(Figure 4), and to AID-sufficient MycI/+ and IgHI/+ B cells (Figure 5
and Figure S9), I-SceI-induced DSBs in either c-myc or IgH alone,
in MycI/+AID/ or IgHI/+AID/ B cells, respectively, failed to pro-
ducec-myc/IgH translocations (Figure 7). Thus, when I-SceI alone
or I-SceI and AID coordinately generate DSBs on both chromo-
somes, they result in c-myc/IgH translocations. In contrast, in
the absence of AID, I-SceI-induced DSBs generated solely at
IgH or c-myc do not produce translocations. We conclude that
AID is essential for the DSBs in both of the chromosomes involved
in c-myc/IgH translocation.
DISCUSSION
DSBs are dangerous lesions because they can lead to genomic
instability and oncogenic chromosomal translocations. Although
DSBs rarely accumulate in somatic cells, they are obligate inter-
mediates in CSR, a reaction that involves introduction of multiple
targeted DSBs in the IgH locus in mature B lymphocytes. The
genome is normally protected from AID-dependent IgH translo-
cations by ATM-, p53-, and p19Arf-dependent pathways that
detect and signal DNA damage and oncogenic stress (Ramiro
et al., 2006). Nevertheless, these protective mechanisms some-
times fail, as evidenced by involvement of the IgH locus in nearly
all cancer-associated chromosomal translocations in mature
B cell lymphomas and multiple myeloma (Kuppers and Dalla-
Favera, 2001).
AID creates the lesions in the IgH locus that lead to transloca-
tions (Franco et al., 2006; Petersen et al., 2001; Ramiro et al.,
2004, 2006). However, DSBs in IgH alone would not be sufficient
for translocation because aberrant joining of heterologous chro-
mosomes requires formation of paired DNA breaks (Richardson
and Jasin, 2000), and the source of DNA damage in the onco-
genes that are translocated in mature B cell malignancies has
not been determined (Kuppers and Dalla-Favera, 2001).
In Burkitt’s lymphoma and in murine plasmacytoma, IgH is
translocated to c-myc, leading to deregulated expression of
c-myc and malignant transformation (Adams et al., 1982, 1983,
1985; Crews et al., 1982; Dalla-Favera et al., 1983; Erikson
et al., 1983; Hamlyn and Rabbitts, 1983; Marcu et al., 1983;
Taub et al., 1982). Recurrent translocation between c-myc and
IgH has been attributed in part to proximity of the two loci in
B cells because of the dynamic relocation of the two genes to
transcription factories after B cell activation (Osborne et al.,
2007; Roix et al., 2003). Consistent with a role for transcription
in facilitating c-myc/IgH translocation, our experiments show
that the DNA region containing the c-myc promoters is required
for efficient translocation in stimulated B cells. However, this ef-
fect does not appear to be due to transcriptionally regulated
proximity of the two genes or accessibility to recombinase, as
indicated by equivalent levels of Cre-mediated translocation be-
tween IgHI and transcriptionally crippled MycD or active MycI al-
leles. In light of the current discussion about ‘‘breakage first’’ or
‘‘contact first’’ models of chromosomal translocations, our data
do not speak directly to the issue of physical proximity but
suggest that proximity is not limiting. Although loss of the
c-myc promoter region interferes with transcription and c-myc/
IgH translocation, it does not interfere with c-myc’s ability to
come into contact with IgH or with its accessibility to Cre.
Instead, it appears that the c-myc promoter region is essential
to recruit AID to initiate DSB formation. This is consistent with the
finding that Ig transcriptional regulators including promoters, en-
hancers, and the E-box motif CAGGTG (Michael et al., 2003) are
involved in targeting AID to Igs (Di Noia and Neuberger, 2007;
Peled et al., 2008; Stavnezer et al., 2008). Although the elements
required for bringing AID to Ig or c-myc DNA have not yet beenCell 135, 1028–1038, December 12, 2008 ª2008 Elsevier Inc. 1033
precisely defined, in vitro experiments with artificial substrates
and in E. coli show that transcription is essential because it ex-
poses single-stranded DNA that is the substrate for AID (Chaud-
huri et al., 2003; Dickerson et al., 2003; Pham et al., 2003; Ramiro
et al., 2003). Furthermore, the formation of R loops during tran-
scription has been proposed to play a role in targeting AID
(Yu et al., 2003). Thus, our observations suggest a transcriptional
requirement for AID targeting to oncogenes, but the mechanism
by which transcription targets AID to any gene remains to be
determined.
Although increased AID expression was found to increase
c-myc/IgH translocation, this effect could have been due to
higher levels of DNA breaks on c-myc or IgH or both (Dorsett
et al., 2008; Ramiro et al., 2006; Takizawa et al., 2008). Previous
work suggested that DSBs in c-myc are AID independent and
might be due to increased susceptibility of fragile non-B-DNA
to environmental agents like reactive oxygen intermediates or
transcriptional or replication-linked DNA damage (Belotserkov-
skii et al., 2007; Boles and Hogan, 1987; Lieber et al., 2003;
Yang and Hurley, 2006). This idea was supported by the finding
of AID-independent DSBs in c-myc in B cell lymphomas (Zan
et al., 2003), the relative rarity of somatic mutations in c-myc
(Liu et al., 2008; Pasqualucci et al., 2001; Shen et al., 1998),
and the lack of deletions or duplications in c-myc that would
mark DSB formation (Gordon et al., 2003; Liu et al., 2008;
Muschen et al., 2000; Pasqualucci et al., 1998, 2001; Shen
et al., 1998). Despite these findings, our experiments show that
AID can indeed induce lesions and mutations at c-myc and dem-
onstrate that AID is essential for the lesions in c-myc that result in
c-myc/IgH translocation. Nevertheless, the absence of easily de-
tectable DNA damage without AID overexpression suggests that
formation of DNA lesions on c-myc may be one of the limiting
factors in c-myc/IgH translocation under physiologic conditions.
Consistent with this notion, we find that increasing the frequency
of DSB formation by the I-SceI endonuclease at c-myc but not
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Figure 6. Translocations Induced by AID,
I-SceI, or Cre in AID/ Cells
(A) Schematic representation of the MycI, Myc+,
and IgHI alleles with the PCR primers for detecting
der15 c-myc/IgH translocations. Triangles repre-
sent loxP sites, and circles point to recognition
sequences for I-SceI.
(B) Representative agarose gels with PCR prod-
ucts corresponding to c-myc/IgH translocations
(as verified by sequencing and/or Southern blot,
see Figure S10). MycI/+ IgHI/+ AID/ B cells
were stimulated with LPS and IL-4 and infected
with AID, I-SceI, or Cre as indicated. DNA equiva-
lents for the indicated number of cells were
assayed in each reaction. Data are from two
independent experiments.
IgH enhances translocation. Since
I-SceI targets c-myc and IgH with similar
efficiency, we can also conclude that
AID-induced DSB formation at c-myc is
lower than at IgH.
Although the DNA lesions introduced by either I-SceI or AID
alone produced c-myc/IgH translocation, the extent of DNA
processing and the structure of the intermolecular joints differed.
The most extensive resection of DNA ends was found at c-myc
when I-SceI mediated translocations in the absence of AID.
Why the same resection was not detected at IgH under the same
conditions is unclear, but the data are consistent with the exis-
tence of locus-specific DNA damage-processing factors (Liu
et al., 2008). Whereas I-SceI-induced breaks were resolved by
a mechanism biased toward junctional microhomology reminis-
cent of alternative nonhomologous end joining (Richardson and
Jasin, 2000), AID breaks produced a combination of blunt and
short microhomology joints similar to those found in class switch
recombination (Stavnezer et al., 2008). The difference in trans-
chromosomal joints between I-SceI and AID may be explained
by recruitment of a distinct set of repair enzymes to the two types
of DNA damage. In the case of I-SceI, a DSB is introduced
directly by the yeast endonuclease and must be recognized by
the DNA damage recognition and repair system before being
processed and joined. In contrast, AID-induced U:G mismatches
are recognized by mismatch and base excision repair enzymes
before recruitment of additional repair factors that then process
the lesions to produce DSBs. Thus, the difference in the joints
produced by I-SceI breaks and AID lesions may in part be due
to the distinct mechanisms that recognize the initial lesion and
produce the DSB.
Although the precise mechanism by which AID introduces
lesions in DNA is still debated, AID is thought to produce U:G
mismatches in DNA by cytidine deamination (Di Noia and Neu-
berger, 2007; Peled et al., 2008; Stavnezer et al., 2008). In B cells
undergoing SHM or CSR, uracyl is detected and removed from
antibody genes by error prone mechanisms leading to mutations
or DSBs. Other genes, including oncogenes, appear to repair
such lesions in a relatively error-free manner, which may explain
the nearly undetectable level of AID-mediated mutation in genes1034 Cell 135, 1028–1038, December 12, 2008 ª2008 Elsevier Inc.
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Figure 7. AID Is Essential for the Lesion in c-myc that Leads to c-myc/IgH Translocation
(A) Top: Schematic representation of the MycI, Myc+, and IgH+ alleles with the PCR primers for detecting der12 and der15 c-myc/IgH translocations. The circle
indicates the I-SceI site. Bottom: A representative ethidium bromide (EtBr) stained agarose gel was also Southern blotted and probed for c-myc and IgH, as in-
dicated, to verify translocations. MycI/+AID/ B cells were stimulated with LPS and IL-4 and infected with an I-SceI-encoding retrovirus. In each lane, 100,000
cells were assayed. No translocations were identified out of 3.4 3 107 cells analyzed. Data are from three independent experiments.
(B) Top: Schematic representation of the Myc+ and IgHI alleles with the PCR primers for detecting der12 and der15 c-myc/IgH translocations. The circle indicates
the I-SceI site. Bottom: A representative ethidium bromide (EtBr) stained agarose gel was also Southern blotted and probed for c-myc and IgH, as indicated, to
verify translocations. IgHI/+ AID/ B cells were stimulated with LPS and IL-4 and infected with I-SceI. In each lane, 100,000 cells were assayed. No translocations
were identified in 6.9 3 107 cells. Data are from seven independent experiments.like c-myc (Table S1) (Liu et al., 2008; Pasqualucci et al., 2001;
Shen et al., 1998). Our experiments reveal that like the error-
prone repair pathways that process the lesions at the IgH locus,
the relatively error-free repair of AID dependent lesions in c-myc
can also lead to oncogene translocation.
EXPERIMENTAL PROCEDURES
Mice
MycD/+, IgHI/+, MycI/+, and AIDCre/+ mice were generated by homologous
recombination in C57BL/6 albino embryonic stem (ES) cells. Details of the tar-
geting vectors, screening by Southern blot, and genotyping PCR are provided
in the legends to the Supplemental Data. AID/ mice (Muramatsu et al., 2000)
were backcrossed to C57BL/6 for at least ten generations. All experiments
were in agreement with protocols approved by the Rockefeller University
and National Institutes of Health (NIH) Institutional Animal Care and Use
Committee.
Retroviruses
Cre, I-SceI, I-SceI*, and AID were PCR amplified and cloned into the pMX-
IRES-GFP plasmid. In I-SceI*, D44A and D145A substitutions to inactivate
the catalytic sites were introduced by PCR (Stoddard, 2005).B Cell Cultures and Retroviral Transduction
Resting B lymphocytes were isolated from mouse spleens by immunomag-
netic depletion with anti-CD43 MicroBeads (Miltenyi Biotech) and cultured at
0.5 3 106 cells/ml in R10 medium: RPMI supplemented with L-glutamine, so-
dium pyruvate, antibiotic/antimycotic, 50 mM 2-mercaptoethanol (all from
GIBCO-BRL), and 10% fetal calf serum (Hyclone). B cells were stimulated in
the presence of 25 mg/ml lipopolysaccharide (LPS, E. coli serotype 0111:B4,
Sigma) and 5 ng/ml mouse recombinant IL-4 (Sigma) and analyzed after
96 hr. For the analysis of translocations in MycD/+ mice (Figure 1D), cultures
were supplemented with 50 ng/ml mouse recombinant BAFF (R&D Systems)
to boost the translocation frequency. For infection experiments, retroviral
supernatants were prepared by cotransfection of BOSC23 cells with pCL-
Eco and pMX-IRES-GFP-derived plasmids (encoding for Cre, I-SceI, I-SceI*,
or AID) with Fugene 6, 72 hr before infection. At 20 and 44 hr of lymphocyte
culture, retroviral supernatants were added, and B cells were spinoculated
at 1150 g for 1.5 hr in the presence of 10 mg/ml polybrene. After 4 hr at
37C, supernatants were replaced with LPS and IL-4 supplemented R10.
B cells were analyzed at 96 hr from the beginning of their culture.
Flow Cytometry and Cell Sorting
For fluorescence-activated cell sorting (FACS) analysis, spleen cell suspen-
sions were stained with fluorochrome-conjugated anti-CD19, anti-CD3, anti-
IgM, anti-IgD, and anti-IgG1 (Pharmingen). Labeling for cell division was atCell 135, 1028–1038, December 12, 2008 ª2008 Elsevier Inc. 1035
37C for 10 min in 5 mM carboxyfluorescein succinimidyl esther (CFSE). In all
experiments, retrovirally infected GFP+ cells were sorted to over 95% purity
with a FACSVantage SE or FACSAria instruments (Becton Dickinson).
RNA Fluorescence In Situ Hybridization
Stimulated splenic B cells were fixed on slides and analyzed by RNA FISH as
described (Gribnau et al., 1998, 2000; Chakalova et al., 2004).
Immuno-FISH
Immunocytochemistry staining followed by fluorescence in situ hybridization
(Immuno-FISH) was as described (Petersen et al., 2001; Difilippantonio
et al., 2000).
PCR Assay for Translocations
PCR reactions were performed on genomic DNA from 105 cells, unless other-
wise indicated. With the Expand Long Template PCR System, nested reac-
tions were performed with the following primers: for derivative chromosome
12 translocations first round, 50-TGAGGACCAGAGAGGGATAAAAGAGAA-30
and 50-GGGGAGGGGGTGTCAAATAATAAGA-30; for derivative chromosome
12 translocations second round, 50-CACCCTGCTATTTCCTTGTTGCTAC-30
and 50-GACACCTCCCTTCTACACTCTAAACCG-30; for derivative chromo-
some 15 translocations first round, 50-ACTATGCTATGGACTACTGGGGTCAA
G-30 and 50-GTGAAAACCGACTGTGGCCCTGGAA-30; for derivative chromo-
some 15 translocations second round, 50-CCTCAGTCACCGTCTCCTCAGGT
A-30 and 50-GTGGAGGTGTATGGGGTGTAGAC-30; for derivative chromo-
some 12 translocations (upstream of switch m) first round, 50-GGCAACTTCAA
ATTCATTAAACCACAT-30 and 50-GGGGAGGGGGTGTCAAATAATAAGA-30;
and for derivative chromosome 12 translocations (upstream of switch m) sec-
ond round, 50-AAATGTGAGTGACCCAGACAACG-30 and 50-GACACCTCCCT
TCTACACTCTAAACCG-30. PCR conditions were according to manufacturer
instructions with 29 cycles for the first round (ten cycles at 92C, 10 s; 60C,
30 s; and 68C, 7 min; followed by 19 cycles at 92C, 15 s; 60C, 30 s; and
68C, 7 min with 20 s of additional extension time per cycle) and 25 cycles
for the second round (ten cycles at 92C, 10 s; 60C, 30 s; and 68C, 4 min;
followed by 15 cycles at 92C, 15 s; 60C, 30 s; and 68C, 4 min with 20 s of
additional extension time per cycle). PCR products were gel purified and
sequenced.
Southern Blotting
Southern blot analysis was performed as described (Ramiro et al., 2006). Oli-
goprobes were as follows: for der15 c-myc, 50-GCCGCCACTTTACTGGACTG
CGCAGG-30; for der15 IgH, 50-GAGGGAGCCGGCTGAGAGAAGTTGGG-30;
for der12 c-myc, 50-GCAGCGATTCAGCACTGGGTGCAGG-30; for der12 IgH
(30 of switch m), 50-CCTGGTATACAGGACGAAACTGCAGCAG-30; and for
der12 IgH (50 of switch m), 50- TTCAGTCATTGCTTTAGGGGGAG-30. p value
was calculated with a two-tailed Fisher’s exact test.
Mutational Analysis
Primers 50-TGGTCTTTCCCTGTGTTCTTTCTG-30 and 50-GACACCTCCCTTCT
ACACTCTAAACCG-30 were used to amplify a portion of c-myc intron 1 with
Pfu polymerase and 25 cycles of amplification (95C, 10 s; 58C, 30 s; and
72C, 90 s), prior to cloning in TOPO vector and sequencing.
SUPPLEMENTAL DATA
SupplementalData include ten figures and four tablesand can be foundwith this
article online at http://www.cell.com/supplemental/S0092-8674(08)01310-X.
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